<DOC>
	<DOC>NCT00913653</DOC>
	<brief_summary>This study assess the safety/tolerability, PK/PD of LCZ696 in patients with stable heart failure.</brief_summary>
	<brief_title>Safety/Tolerability, Pharmacokinetics/Pharmacodynamics (PK/PD) of LCZ696 in Patients With Stable Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>Patients with documented heart failure (NYHA class IIIV) Use of both ACEi and ARB, ACEi and DRI, ARB and DRI treatment, or all three medications at Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Heart failure</keyword>
	<keyword>LCZ696</keyword>
</DOC>